Nicole Casasanta, Instructor of Medicine, Medical Oncology at Yale Cancer Center, shared on LinkedIn:
“Excited to share our publication evaluating TP53 alterations with a closer look at TP53 Y220C alteration in metastatic breast cancer (MBC) JCO Journals.
Title: TP53 Genomic Alterations Including Targetable Y220C Mutation in Advanced Breast Cancer
Authors: Nicole A. Casasanta, Adriana Kahn, Neal Fischbach, Dean Pavlick, Patricia LoRusso, Ethan S. Sokol, Ryon Graf, Julia C.F. Quintanilha, Gerald Li, Jeffrey S. Ross, Maryam B. Lustberg
- 53% of pts with MBC had any TP53 alteration of which 2% were TP53 Y220C
- Among 217 pts with TP53 Y220C, 56.2% had TNBC, 30.4% HR+, 13.4% HER2
- TP53 non-Y220C mutants had a higher frequency of TMB ≥ 10 mut/Mb vs TP53wt (8.1% vs 5.5%, p<.0001) and TMB ≥ 20 mut/Mb (2.4% vs 1.7%, p<.0001)
- Additional alterations more frequent in those with TP53 alterations (Y220C and non-Y220C) versus TP53wt cases included BRCA1, ERBB2, PTEN, RB1, AKT2, KRAS, MTAP, NTRK1, and VEGFA.
With the development of retzatapopt, combination therapies should be explored for those with MBC and TP53 Y220C alterations.”
To which Maryam Lustberg, Director Breast Center/Chief Breast Oncology at Yale University School of Medicine, added:
“Important paper from my group highlighting a targetable genomic alteration in MBC.”
Other articles about metastatic breast cancer on OncoDaily.